The Study on COgnition and Prognosis in the Elderly (SCOPE) was a multinational, randomised, double-blind study to assess the effects of candesartan 8-16 mg daily on cardiovascular events and cognitive function in elderly patients (aged 70-89 years) with mild to moderate hypertension. A total of 4937 patients were randomised to candesartan or placebo with other antihypertensive drugs (mostly diuretics, beta-blockers, and calcium antagonists) added as needed to control blood pressure. Only 16% of the patients in the control group received placebo alone. The mean follow-up was 3.7 years. The aim of this health-related quality of life (HRQL) substudy analysis was to investigate changes in HRQL during antihypertensive treatment, and possible differences in patients receiving candesartan-based or other antihypertensive treatment. Three validated HRQL instruments were used: the Psychological General Wellbeing (PGWB) Index, the Subjective Symptoms Assessment Profile (SSA-P), and the EuroQoL Health Utility Index (EuroQoL). The HRQL was generally good at baseline and well preserved during follow-up in the presence of substantial blood pressure reductions in both treatment groups. Several of the observed changes in score from baseline to last visit favoured candesartan-based compared to control treatment, particularlyIntroduction Improved possibilities to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQL). Since treatment of chronic diseases is often not curative, but aims to improve function, limit disease progression and ameliorate suffering, any negative influence of the treatment on HRQL must be limited as far as possible. Symptoms, physical, or biochemical measures of disease activity are the main tools employed to evaluate the effects of drug therapy. These tools, however, do not reflect the patient's perception of HRQL. Yet, a patient's perception is largely responsible for whether or not a patient will adhere to and benefit from treatment. [1] [2] [3] Thus, it is important to further explore the influence of new drugs on HRQL. This is particularly relevant to antihypertensive drugs, as adherence to such treatment is often poor, 4, 5 possibly since the disorder in most cases is asymptomatic, whereas the treatment may cause symptoms 6 and therefore affect the patient's HRQL. Indeed, many physicians are hesitant to prescribe antihypertensive treatment to elderly patients with mild to moderate hypertension because of concern for a possible negative effect of the drug(s) on HRQL.
Candesartan cilexetil (candesartan) is extensively used for the treatment of hypertension. Like other AT 1 -receptor blockers, it is an effective and welltolerated drug. 7 In randomised, double-blind clinical studies, the tolerability of candesartan has been similar to that of placebo. 8 So far, little information on the influence of candesartan on HRQL is available, although well-maintained HRQL during treatment with candesartan was reported in a study in women aged 40-69 years. 9 HRQL was extensively studied in the recently completed Study on COgnition and Prognosis in the Elderly (SCOPE), and this article presents the main results.
The main purpose of SCOPE was to evaluate the effect of candesartan 8-16 mg daily on major cardiovascular events (cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction), cognitive function, and dementia in elderly patients (aged 70-89 years) with mild to moderate hypertension. The rationale, objectives, design, inclusion and exclusion criteria, methods, and main results have been published. 10, 11 In brief, SCOPE was a multinational, randomised, double-blind, controlled study with 4937 patients followed for a mean of 3.7 years. Any previous antihypertensive treatment was standardised to hydrochlorothiazide 12.5 mg daily and kept throughout the study. It was initially intended as a placebo-controlled study, but because of changing treatment guidelines and for ethical reasons, the study protocol was amended to recommend open-label active antihypertensive therapy in both treatment arms if the blood pressure remained high (systolic X160 mmHg and/or diastolic X90 mmHg). As a consequence, SCOPE became a comparison between a candesartan-based treatment regimen and a regimen not containing candesartan. In all, 49% of the patients in the candesartan group and 66% of those in the control group actually received open-label antihypertensive therapy after randomisation (mostly diuretics, beta-blockers, and calcium antagonists). Only 16% of the patients in the control group received placebo alone.
Both treatment regimens effectively lowered blood pressure; the mean blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/ 82 mmHg in the control group. The rate of the primary end point, major cardiovascular events was 26.7 per 1000 patient-years in the candesartan group and 30.0 per 1000 patient-years in the control group, a risk reduction with candesartan of 10.9% (P ¼ 0.19). For nonfatal stroke there was a statistically significant risk reduction with candesartan of 27.8% (P ¼ 0.04). Cognitive function (as measured with the Mini Mental State Examination, MMSE) was high at baseline (randomisation) and well maintained in both treatment groups during follow-up. There was no difference between the treatment groups in change in cognitive function (MMSE score) or in the proportion of patients who developed dementia.
In SCOPE, the HRQL was studied in a subset of patients. The main objectives of this analysis were to investigate changes in HRQL during antihypertensive treatment in the elderly, and to assess possible differences in the impact on HRQL in patients receiving candesartan-based or other antihypertensive treatment.
Patients and methods
The HRQL substudy was run in six countries with a total of 314 centres, mainly representing primary care, and involved 2850 patients, that is, more than 50% of the whole SCOPE population. All patients at the 314 centres were included in the HRQL substudy. In all, 13% of the patients included in the HRQL substudy were recruited in France, 22% in Germany, 21% in The Netherlands, 10% in Sweden, 31% in the UK, and 4% in the USA.
The patients were instructed how to fill in the HRQL questionnaires at a training session during the run-in phase (before randomisation). At baseline, and at specific time points during the treatment phase, the patients completed the HRQL questionnaires at the clinic before other measurements (eg blood pressure) were made. The patients were allowed 15-20 min to sit alone and fill in the questionnaires in peace and quiet. The person responsible for the administration of the HRQL questionnaires checked that all questions were completed.
The Psychological General Well-Being (PGWB) Index, the Subjective Symptom Assessment Profile (SSA-P), and the EuroQoL Health Utility Index (EuroQoL) were selected for the assessment of HRQL on the basis of being well recognised and validated. The PGWB measures well-being 12 and includes a Total score, which is divided into six dimensions depicting Anxiety, Depressed mood, Positive wellbeing, Self-control, General health, and Vitality. The response format uses a six-point scale. The higher the value, the better the patient. The Total score gives a maximum score of 132 and a minimum of 22. The SSA-P records changes in subjective symptoms related to hypertension and to different antihypertensive drugs. 13 It employs a seven-point scale. Low values indicate mild symptoms (1 ¼ no symptoms) and high values severe symptoms. Three of the six dimensions in the SSA-P were used in SCOPE: Cardiac symptoms, Dizziness, and Peripheral/circulatory symptoms. In addition, 17 single items from this instrument were used. The EuroQoL 14, 15 captures physical, mental, and social functioning with the time frame 'today'. The 100-point visual analogue scale, measuring Current health, was used; 100 indicate the best imaginable health state and 0 the worst.
Statistics
The stastical analysis was carried out according to the intention-to-treat approach. The Total score and the scores for the six dimensions in the PGWB, as well as the three dimensions in SSA-P, were calculated by summarising the item values in each dimension. Dimensional scores in the PGWB and the SSA-P were only calculated if at least 60% of the items in a dimension were available, otherwise they were set as missing.
Analysis of covariance was used to analyse the change in score from baseline to the last available score, which was assumed to follow a general linear model with fixed effects for country, treatment, interaction between treatment and country, and baseline value as a covariate. The 95% confidence intervals (CIs) for the difference between the true treatment effects, adjusted for all factors in the model, were calculated for each variable. The analysis used the last value carried forward approach. In order to limit the number of tests, only descriptive results were processed for the single items in the SSA-P.
Results
Patient characteristics in the candesartan group (n ¼ 1428) and the control group (n ¼ 1422) were similar at baseline, Table 1 . These were also similar to the characteristics of the whole SCOPE population. Two-thirds of the patients in both treatment groups were female. The mean age was 76 years, and some 20% of the patients were aged 80 years or above, in both groups. Approximately, 90% had been educated to at least primary school level. The mean blood pressure at baseline (untreated and hydrochlorothiazide-treated patients combined) was 167/91 mmHg in both treatment groups. Rather few patients in each treatment group had previously suffered a cardiovascular event. Approximately, 10% of the patients had diabetes on entry to the study.
More than 90% of all patients in the HRQL study had evaluable HRQL data from one or more visits after baseline. The mean PGWB scores at baseline and at the last available visit in the candesartan group and the control group are shown in Table 2 . The table also gives the adjusted changes from baseline to the last visit in each treatment group as well as the differences in change between groups. The mean PGWB Total score at baseline was 106.0 and 106.3 in the candesartan and control groups, respectively, indicating a relatively high general well-being in most patients. The adjusted mean changes (reductions) in PGWB scores were generally modest in both treatment groups, and the betweengroup differences in change were relatively small. The reductions were numerically smaller in the candesartan group than in the control group for all PGWB dimensions, except Depressed mood (identical reductions). For Anxiety and Positive wellbeing, low P-values indicated an advantage for candesartan-based compared to control treatment (P ¼ 0.01 and 0.04, respectively). It is worth noting that the P-value for Total score was also low (P ¼ 0.06).
The mean scores in the SSA-P dimensions at baseline were low, indicating no or very mild symptoms in most patients, Table 3 . The adjusted mean changes (increases) in the SSA-P dimension scores were generally small, as were the differences in change between the treatment groups. For Cardiac symptoms (heart beating rapidly, heart beating slowly, palpitations), a low P-value indicated an advantage for candesartan-based treatment (P ¼ 0.03). Dizziness, a common symptom of marked blood pressure reduction, was similar in both treatment groups. The mean values for the 17 single items at baseline and at the last visit in the candesartan group and the control group are shown in Figure 1 . The highest scores were reported for 'Trouble muscle/joints' both at baseline (mean score 2.5) and the last visit (mean score 2.7) in both treatment groups. No patient reported any subjective symptoms as moderate or above (X4 on the sevenpoint scale). The mean changes for the SSA-P dimensions and single items in the candesartan group and the control group were small (at most Health-related quality of life in elderly hypertensives7 0.3), and the differences in change between the treatment groups were minor. The mean scores in the EuroQoL at randomisation were relatively high in both treatment groups, indicating that the Current health was perceived as rather good by most patients, Table 4 . The adjusted mean changes (reductions) in scores were relatively small in both treatment groups, and even smaller in the candesartan group than in the control group (P ¼ 0.008).
Discussion
This analysis showed that HRQL in the SCOPE patients was generally good at baseline and well Table 3 Subjective symptoms as evaluated with the SSA-P Baseline Last visit Change (adjusted) Difference in change (adjusted)
Lower Upper
Peripheral/circulatory symptoms Control Candesartan Figure 1 Mean values at baseline and last visit for single items in the SSA-P.
Health-related quality of life in elderly hypertensivespreserved during follow-up in the presence of substantial blood pressure reductions both in patients in the candesartan group and in the control group. For four HRQL variables (PGWB Anxiety and Positive well-being, SSA-P Cardiac symptoms, and EuroQoL Current health), the analysis indicated an advantage of candesartan-based treatment compared to control treatment. Although the HRQL substudy did not include patients from all countries that participated in SCOPE, the patients in the substudy were representative for the entire SCOPE study population as indicated by similar baseline characteristics, as reported previously. 16 The results in the present analysis are in agreement with several other studies showing little influence of antihypertensive treatment on HRQL, 17, 18 although there are studies reporting both improved 19, 20 and worsened HRQL. 21, 22 In the hypertension optimal treatment (HOT) study 23 there was some evidence to suggest that lower levels of achieved blood pressure were associated with improved PGWB scores. The fact that a slight deterioration was found in most HRQL variables in SCOPE might be explained by good HRQL at baseline, high age of the patients, and long followup (3.7 years). In this context, it is worth noting that the blood pressure reduction in the candesartan group was somewhat greater than in the control group. This might partly explain the even less influence on several HRQL variables in the candesartan group than in the control group.
It is sometimes difficult to interpret the results in HRQL studies. Small changes in HRQL scores may be statistically significant but of no or limited clinical importance for the patient. One method to determine the clinical importance is to use the patients' own perception of a meaningful change in HRQL. The minimal important difference has been defined as 'the smallest difference in score in the domain of interest that patients perceive as beneficial and would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient's management'. 24 However, other definitions have been suggested. [25] [26] [27] If the minimal important difference for a clinical trial outcome is known, the interpretation becomes easier. 28 Jaeschke et al 29 have shown that when questionnaires present response options in the form of seven-point scales with verbal descriptions for each option, the smallest difference that patients consider important is often approximately 0.5 scores. This finding applies across different areas of function. 24, [29] [30] [31] [32] Our elderly hypertensive patients assessed their perceived subjective symptoms on a seven-point disease-specific questionnaire (SSA-P). The increase in different subjective symptoms in SCOPE was at most 0.3 scores, that is, most likely of no clinical importance. In this context, it is worth noting that a disease-specific instrument, such as the SSA-P, should be more suited to assess symptoms that are relevant for the studied population than a generic instrument. 33 However, interpretation based on mean values must be carried out with caution, since individual patients may perceive large improvements or deteriorations during intervention. 34 When measuring HRQL in clinical trials, the possible influence on the responses of results from physical examinations, for example, blood pressure, must be considered. In the present study, this potential problem was minimised by administering the HRQL questionnaires before any other examinations were carried out.
Several HRQL instruments, each with many dimensions and single items, are often used in the evaluation of HRQL in clinical studies. This often leads to a large number of statistical tests being carried out and an increased risk of statistically significant findings occurring by chance in the absence of adjustment of the P-values to keep the alpha error at the 5% level. In the present report no adjustment for multiple comparisons was carried out for two main reasons. Firstly, the analysis of HRQL in SCOPE was intended to be exploratory rather than confirmatory. Secondly, there is no concensus on how to adjust. Simply adjusting according to Bonferroni would certainly be too conservative, partly because many of the HRQL variables are closely correlated.
In conclusion, HRQL in SCOPE was generally good at baseline and well preserved during followup in the presence of substantial blood pressure reductions both in patients in the candesartan group and in the control group. For four HRQL variables (PGWB Anxiety and Positive well-being, SSA-P Cardiac symptoms, and EuroQoL Current health), Health-related quality of life in elderly hypertensivesthe analysis indicated an advantage of candesartanbased treatment compared to control treatment. This favourable result may be related to the somewhat lower blood pressure associated with candesartanbased treatment. There should be no reason to withhold modern antihypertensive therapy in elderly patients due to concerns for a negative effect on HRQL.
